ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages ESSA Pharma Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EPIX

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of ESSA Pharma Inc. during the specified Class Period of the upcoming lead plaintiff deadline on March 25, 2025 [1] Group 1: Class Action Details - Investors who purchased ESSA Pharma Inc. securities between December 12, 2023, and October 31, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6] - The lawsuit claims that ESSA Pharma Inc. misled investors regarding the efficacy of masofaniten in combination with enzalutamide for treating prostate cancer, overstating its clinical and commercial prospects [5] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]